Media Staff

A new program is training nurses across the country to identify the needs of cancer survivors and to help patients and their families achieve the best possible quality of life after treatment.

For the 23rd year in a row, Memorial Sloan-Kettering is ranked as one of the best hospitals for cancer care nationally according to U.S. News & World Report, appearing at No. 2 on the 2012-13 list.

A new study confirms that female childhood cancer survivors who were treated with radiation to the chest have a high risk of developing breast cancer at a young age – a risk that is comparable to that of women who have mutations in BRCA1 or BRCA2 genes.

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan-Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Researchers at Memorial Sloan-Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

Five Memorial Sloan-Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.